Ozempic 1mg Compared to Mounjaro: What the Dose Equivalence Question Really Asks

The decision you're probably trying to make, and why the framing matters

Most people asking about an Ozempic 1mg equivalent to Mounjaro are not moving between diabetes medicines. They have seen Ozempic mentioned alongside weight-loss treatments and want to know how the doses line up. It is a reasonable question, and the honest answer shifts things a little.

Ozempic contains semaglutide, which is also the active ingredient in Wegovy. The difference is the licensed use: Ozempic is approved by the MHRA for blood-sugar control in type 2 diabetes; Wegovy is approved for weight management. Using Ozempic off-label for weight loss is not something a regulated UK prescriber would do when a licensed alternative exists, and the NHS medicines information for semaglutide is clear on the distinction. So the real comparison, if you are considering weight-loss treatment, is between Wegovy and Mounjaro, and those two medicines have different mechanisms, different titration ladders, and different trial evidence behind them.

A dose-equivalence table between Ozempic and Mounjaro would be misleading because the medicines do not share a common unit of effect. Mounjaro is a dual GIP and GLP-1 receptor agonist; semaglutide (in any brand) acts on the GLP-1 pathway alone. You can read about how an Ozempic equivalent dose to Mounjaro is approached, which sets out why the mechanisms make direct comparison so difficult, and even there, direct milligram conversion is not straightforward.

What the evidence actually shows when tirzepatide and semaglutide are placed side by side

The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, compared tirzepatide with semaglutide 2.4mg directly in adults with obesity and no diabetes over 72 weeks. Tirzepatide produced greater average weight reduction. NICE's appraisal of tirzepatide (TA1026) notes that indirect comparisons in its evidence review also favour tirzepatide, though it acknowledges the limitations of cross-trial analysis. Wegovy at 2.4mg produced around 15% average weight loss in the STEP 1 trial (68 weeks); tirzepatide at 15mg produced around 20–21% average weight loss in SURMOUNT-1 (72 weeks). These are trial averages. Individual results vary, and factors including starting weight, dose tolerance, and adherence all play a role.

The gap narrows somewhat with Wegovy's newer 7.2mg dose, approved by the MHRA in January 2026, which reported around 20.7% average weight loss over 72 weeks. That approval means semaglutide now has a maintenance option that sits much closer to tirzepatide's headline results. If you want to understand what a Wegovy 1mg dose is equivalent to in Mounjaro terms, that page covers the comparison in detail across both medicines' full ranges. A fuller look at how the two compare across their full dose ranges is also covered on the Wegovy vs Mounjaro page.

The point is not to declare a winner. It is to illustrate why comparing Ozempic 1mg to any Mounjaro dose sidesteps the actual question, a dose of a diabetes medicine cannot be mapped to a weight-loss medicine that uses an entirely different mechanism.

A factual comparison of the UK-licensed weight-loss options

The table below sets out the factual differences between Wegovy and Mounjaro for weight management, using UK-licensed information. Ozempic is included solely to show why it sits outside this comparison.

For a closer look at how individual Mounjaro and Wegovy doses relate to each other, the dose chart comparing Ozempic and Mounjaro addresses the mapping question in more detail, including why cross-medicine conversion has limits. If you are also curious about what Mounjaro 5mg is equivalent to in Wegovy terms, that page explores where those two medicines sit relative to each other at that particular dose. Pricing context for both licensed treatments is covered on the Mounjaro and Wegovy price comparison page.

What comes next if you are considering treatment

Mounjaro and Wegovy are both prescription-only medicines. The decision between them is not one a milligram conversion settles, it depends on your health history, existing conditions, what medications you take, and how your body is likely to respond. Our clinical team, led by GPhC-registered prescribers, reviews each consultation personally before any treatment is approved. There is a common assumption that switching from one GLP-1 medicine to another is a straightforward swap; in practice it involves a clinical reassessment, because tolerability and effect are individual. That assumption is worth letting go early.

If you are already on a weight-loss medicine and considering a switch, or if you are starting for the first time, the free consultation at nume is the right place to start. A prescriber will look at what suits your circumstances, not just what scored highest in a trial. Which treatment fits you is a clinical decision made with our prescribers, not something a comparison table can settle on its own.

You can also browse an overview of available treatments on the weight-loss treatment page, or read more about how the service works on the about us page. Any other questions are covered in the FAQs.